Status and phase
Conditions
Treatments
About
The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.
Full description
This is a phase II, open label, randomized study in patients with unresectable Stage III or Stage IV malignant melanoma. Patients will be randomly assigned to two different doses of RTA 402 administered orally once daily for 28 consecutive days, for up to 18 months.
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal